Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human CXCR6 full length protein-synthetic nanodisc FLP100124

PICTO_DIMABiotech.jpg


The add to cart button will appear once you select the values above

Specifications

10µg / 50µg / 100µg

Alternative names:

BONZO; CD186; CDw186; STRL33; TYMSTR

Description:

Human CXCR6 full length protein-synthetic nanodisc

Background:

A G protein-coupled receptor with seven transmembrane domains that belongs to the CXC chemokine receptor family. This family also includes CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, and CXCR7. This gene, which maps to the chemokine receptor gene cluster, is expressed in several T lymphocyte subsets and bone marrow stromal cells. The encoded protein and its exclusive ligand, chemokine ligand 16 (CCL16), are part of a signalling pathway that regulates T lymphocyte migration to various peripheral tissues (the liver, spleen red pulp, intestine, lungs, and skin) and promotes cell-cell interaction with dendritic cells and fibroblastic reticular cells. CXCR6/CCL16 also controls the localization of resident memory T lymphocytes to different compartments of the lung and maintains airway resident memory T lymphocytes, which are an important first line of defense against respiratory pathogens. The encoded protein serves as an entry coreceptor used by HIV-1 and SIV to enter target cells, in conjunction with CD4.

Protein families:

Druggable Genome, GPCR, Transmembrane

Protein pathways:

Chemokine signaling pathway, Cytokine-cytokine receptor interaction

Expression host:

HEK293

Target:

CXCR6

Molecular weight:

The human full length CXCR6 protein has a MW of 39.3 kDa

Formulation / Reconstitution:

Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.

Usage:

Research use only

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com